{
  "title": "Paper_491",
  "abstract": "pmc Proc Natl Acad Sci U S A Proc Natl Acad Sci U S A 2 pnas PNAS Proceedings of the National Academy of Sciences of the United States of America 0027-8424 1091-6490 National Academy of Sciences PMC12478140 PMC12478140.1 12478140 12478140 40956890 10.1073/pnas.2511899122 202511899 1 video Video research-article Research Article neuro Neuroscience 424 Biological Sciences Neuroscience PI31 expression is neuroprotective in a mouse model of early-onset parkinsonism Rodriguez Jose A.  a  1 https://orcid.org/0009-0000-1813-1103 Minis Adi  a  1 Aref Rasha  a  2 https://orcid.org/0000-0001-6971-8609 Nguyen Hieu Hoang Minh  a  2  3 https://orcid.org/0000-0001-9195-1757 Sun Fiona  a https://orcid.org/0009-0004-9546-3178 Steller Hermann steller@rockefeller.edu  a  4 https://orcid.org/0000-0002-4577-4507 a Strang Laboratory of Apoptosis and Cancer Biology, The Rockefeller University New York NY 10065 4 steller@rockefeller.edu Edited by Moses Chao, New York University Langone Medical Center, New York, NY; received May 13, 2025; accepted August 7, 2025 1 2 3 16 9 2025 23 9 2025 122 38 497776 e2511899122 13 5 2025 07 8 2025 16 09 2025 30 09 2025 30 09 2025 Copyright © 2025 the Author(s). Published by PNAS. 2025 https://creativecommons.org/licenses/by-nc-nd/4.0/ This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) Significance Mutations in FBXO7/PARK15 Drosophila Fbxo7 Neurodegenerative diseases present one of the most significant global health challenges. These disorders are defined by the accumulation of abnormal protein aggregates that impair synaptic function and cause progressive neuronal degeneration. Therefore, stimulating protein clearance mechanisms may be neuro-protective. Variants in FBXO7/PARK15 Fbxo7 Fbxo7 Fbxo7 neurodegenerative disease ubiquitin proteasome system synapse axonal transport proteostasis Pershing Square Foundation (PSF) 100010304 n/a Hermann Steller NIH RO1GM60124 Hermann Steller pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes Most age-related neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) are defined by the accumulation of abnormal protein aggregates ( 1 11 4 12 14 15 17 18 19 4 20 23 24 31 31 32 33 37 32 38 Drosophila 32 35 PMSF1 FBXO7 39 44 39 47 Fig. 2 A 33 48 49 Fbxo7 Fbxo7 nutcracker (ntc) Drosophila Fbxo7 Fbxo7 Results Elevated PI31 Can Compensate for the Conditional Loss of nutcraker Drosophila Inactivation of nutcracker (ntc) Drosophila Fbxo7 50 ntc 32 51 ntc ntc f07259/ms771 Fig. 1 A B Movies S1 S2 Fig. 1 A B Movies S1 S2 −/− −/− 32 51 ntc f07259/ms771 ntc f07259/ms771 Fig. 1 A B Movie S3 ntc f07259/ms771 Fig. 1 C D Fig. 1. ntc Drosophila A B ntc A ntc f07259/ms771 f07259/ms771 /+ ntc f07259/ms771 / x y B ntc f07259/ms717 ntc f07259/ms771 /+ ntc f07259/ms771 / Drosophila C D ntc f07259/ms771 ntc f07259/ms771 C ntc f07259/ms771 ntc f07259/ms771 /+ ntc f07259/ms771 / D ntc f07259/ms771 f07259/ms771 /+ ntc f07259/ms771 / P P P P Transgenic PI31 Expression Can Suppress Neurological Phenotypes in Fbxo7 Inactivation of Fbxo7 33 Fig. 2 A PI31 Fbxo7 Fbxo7 PI31 fl/fl CreERt2 Fig. 2 B SI Appendix 52 53 Fbxo7 PI31 fl/fl Cre/+ Fig. 2 C K 35 PI31 fl/fl Cre/+ Fbxo7 fl/fl Cre/+ Fig. 2 C Fig. 2 D G Fig. 2 E J Fig. 2 E K Fig. 2 H I PI31 fl/fl Cre/+ 35 54 Fbxo7 PI31 Fig. 2. Motor neuron-specific inactivation of Fbxo7 A Fbxo7 Fbxo7 B PI31 PI31 fl/fl PI31 fl/fl CreERt2/+ t P P C Fbxo7 fl/fl Cre/+ PI31 fl/fl Cre/+ Fbxo7 fl/fl Cre/+ Fbxo7 fl/fl E I Fbxo7 H I Fbxo7 fl/fl Cre/+ H I Insets G J K D E F I t P Fbxo7 fl/fl Fbxo7 fl/fl Cre/+ Because inactivation of Fbxo7 Fig. 2 A Fbxo7 fl/fl Cre/+ Fbxo7 TgPI31 SI Appendix A Hb9 Cre Chat Cre Chat Cre Hb9 Cre Hb9 Cre SI Appendix B H TgPI31 PI31 fl/fl Cre SI Appendix B H TgPI31 Fbxo7 fl/fl Cre Fbxo7 fl/fl Cre Movie S4 Fig. 3 A B Fbxo7 fl/fl Cre PI31 fl/fl Cre Fbxo7 fl/fl Cre Fig. 3 C D F G I J Fbxo7 fl/fl Cre Fbxo7 fl/fl Cre Fig. 3 A B Movies S5 S6 Fig. 3 E H I J Fbxo7 Fig. 3. Transgenic expression of PI31 rescues Fbxo7 knockout pathology. ( A B Fbxo7 fl/fl Cre Fbxo7 fl/fl Cre A Fbxo7 fll+ Cre , Fbxo7 fl/fl Cre Fbxo7 fl/fl Cre B Fbxo7 fl/fl Cre Fbxo7 fl/fl Cre C J Fbxo7 TgPI31 C H C E F H I J t P P Fbxo7 fl/fl Cre Fbxo7 fl/fl Cre Transgenic Expression of PI31 Suppresses Phenotypes of Panneuronal and Whole-Body Inactivation of Fbxo7 Variants of FBXO7 Fbxo7 Actl6b Cre BAF53b Cre 55 Fbxo7 TgPI31 Fig. 4 55 Fbxo7 Fbxo7 Fbxo7 tm1b(EUCOMM)Hmgu Fbxo7 KO/KO Fbxo7 tmd(EUCOMM)Hmgu Fbxo7 KO/KO SI Appendix Fbxo7 43 48 Fbxo7 fl/fl Cre Fig. 4 A B TgPI31 Fbxo7 fl/fl Cre/+ Fbxo7 fl/fl Cre/+ Fig. 4 C Fbxo7 KO/KO Fbxo7 fl/fl Cre/+ Fig. 4 D Fbxo7 56 Fbxo7 fl/fl Cre/+ Fig. 4 E Fbxo7 fl/fl Cre/+ Fig. 4 C E Fbxo7 KO/KO Fbxo7 fl/fl Cre/+ Fig. 4 F Fbxo7 Fig. 4. Elevated expression of PI31 suppresses phenotypes of panneuronal inactivation of Fbxo7 A Fbxo7 Fbxo7 fl/fl Cre/+ TgPI31 Fbxo7 fl/fl Cre/+ Fbxo7 fl/fl Fbxo7 fl/fl Fbxo7 fl/fl Cre/+ Fbxo7 fl/fl Cre/+ B Fbxo7 Fbxo7 fl/fl Cre/+ TgPI31 Fbxo7 fl/fl Cre/+ Fbxo7 fl/fl Cre/+ Fbxo7 fl/fl Cre/+ P C Fbxo7 TgPI31 Fbxo7 fl/fl Fbxo7 fl/fl Fbxo7 fl/fl Cre/+ Fbxo7 fl/fl Cre/+ D E Fbxo7 fl/fl Cre/+ D E TgPI31 Fbxo7 Fbxo7 fl/fl Fbxo7 fl/fl Fbxo7 fl/fl Cre/+ Fbxo7 fl/fl Cre/+ C E P P P F Fbxo TgPI31 ActI6b Cre TgPI31 Loss of Fbxo7 Fbxo7 57 Fbxo7 Fbxo7 TgPI31cs 35 TgPI31cs PI31 PI31 KO/KO Psmf1 tm1d(EUCOMM)Hmgu PI31 KO/+ PI31 KO/+ PI31 KO/KO TgPI31cs TgPI31cs PI31 KO/KO PI31 KO/KO TgPI31cs Fig. 5 A Fig. 5. Expression of PI31 suppresses phenotypes of whole-body Fbxo7 A PI31 KO/KO TgPI31cs PI31 KO/KO t P PI31 KO/KO B TgPI31cs Fbxo7 KO/KO Fbxo7 KO/KO Fbxo7 KO/KO Fbxo7 KO/KO P C Fbxo7 KO/KO Fbxo7 KO/KO TgPI31cs Fbxo7 KO/KO Fbxo7 fl/fl Fbxo7 KO/KO Fbxo7 fl/fl Fbxo7 KO/KO Fbxo7 KO/KO D E Fbxo7 KO/KO D E Fbxo7 KO/KO TgPI31cs FBXO7 KO/KO Fbxo7 fl/fl Fbxo7 KO/KO Fbxo7 KO/KO Fbxo7 KO/KO P P P P We then tested whether the TgPI31cs Fbxo7 Fbxo7 tm1d(EUCOMM)Hmgu Fbxo7 KO/KO SI Appendix Fbxo7 KO/KO FBXO7 KO/KO 48 Fbxo7 KO/KO Fig. 5 B Fbxo7 KO/KO Fig. 5 C Fbxo7 KO/KO TgPI31cs Fbxo7 KO/KO Fig. 5 B Fig. 5 B C TgPI31cs Fbxo7 KO/KO TgPI31cs Fbxo7 KO/KO Fbxo7 KO/KO TgPI31cs TgPI31cs Fbxo7 KO/KO TgPI31cs Fig. 5 B C TgPI31 Fbxo7 KO/KO Fbxo7 KO/KO Fbxo7 KO/KO Fig. 5 D E TgPI31cs Fig. 5 D E Tau, a Biomarker for Neurodegenerative Diseases, Is Hyperphosphorylated in Brains of Fbxo7 Reduced function of either Fbxo7 or PI31 results in early-onset parkinsonism that is accompanied by additional neurological and cognitive symptoms ( 39 41 43 44 PI31 42 58 Fbxo7 59 60 Fbxo7 Fig. 6 A Fbxo7 Fbxo7 KO/KO Fig. 6 G I Fbxo7 KO/KO Fig. 6 G H Fbxo7 KO/KO TgPI31cs Fig. 6 G H Fbxo7 SI Appendix Fbxo7 Fbxo7 Fbxo7 Fig. 6 C F 33 Fbxo7 KO/KO Fig. 6 C D Fbxo7 Fig. 6. Loss of Fbxo7 A Fbxo7 Fbxo7 fl/fl Cre/+ TgPI31 ActI6b Cre TgPI31 B C E F G I Fbxo7 Fbxo7 KO/KO G B C F TgPI31cs Fbxo7 fl/fl TgPI31cs/+ Fbxo7 fl/fl Fbxo7 fl/fl Fbxo7 KO/KO Fbxo7 KO/KO Fbxo7 KO/KO TgPI31cs D F H I TgPI31cs Fbxo7 fl/fl Fbxo7 fl/fl Fbxo7 KO/KO Fbxo7 KO/KO Fbxo7 KO/KO P P P Discussion Variants in FBXO7 39 40 45 47 Fbxo7 Drosophila Fbxo7 Fbxo7 Fbxo7 Fbxo7 Fig. 5 B Figs. 4 5 Fig. 6 C D F Fbxo7 KO/KO Fbxo7 Fig. 5 Drosophila The extent to which loss of Fbxo7 61 Fbxo7 45 47 50 62 65 Fbxo7 Fbxo7 48 32 35 Fbxo7 Drosophila 33 Fbxo7 44 47 49 50 62 65 69 Fbxo7 KO/KO TgPI31cs Fbxo7 Drosophila In addition to its interaction with Fbxo7, recent work also links PI31 directly to human disease. Results from a pedigree analysis showed that PSMF1 44 44 PSMF1 FBXO7 42 44 47 PSMF1 42 44 PI31 stimulates protein breakdown in vivo by at least two mechanisms. First, PI31 promotes the assembly of 19S and 20S subunits into 26S particles, which are the primary proteolytic machines responsible for the regulated degradation of poly-ubiquitinated intracellular proteins ( 23 38 70 32 SI Appendix 32 32 35 71 74 21 75 76 S 77 78 81 Fbxo7 We show that Fbxo7 Fig. 6 58 82 83 84 85 Interestingly, tau stabilizes microtubules in neurons and supports axonal transport of proteins and organelles. The fact that Fbxo7 86 PSMF1 FBXO7 Our findings have important implications for the possible development of therapeutic strategies to treat age-related neurodegenerative diseases associated with aggregate-prone proteins. Impaired activity of the UPS is well documented in age-related neuronal degeneration, and efforts to stimulate proteasome activity to promote clearance of aggregate-prone pathognomonic proteins have been made ( 72 87 88 87 89 92 PMSF1 FBXO7 Summary of Methods. We used Drosophila FBXO7 nutcracker FBXO7 Fbxo7 Fbxo7 KO Fbxo7 Hb9 Cre Chat Cre Actl6b Cre Fbxo7 SI Appendix Supplementary Material Appendix 01 (PDF) Movie S1. Representative movie of Prosβ5-RFP mobility in motor neurons of Drosophila ntc f0259 Movie S2. Representative movie of Prosβ5-RFP mobility in motor neurons of Drosophila ntc f0259/ms771 ntc f0259 ntc ms771 Movie S3. Representative movie of Prosβ5-RFP mobility in motor neurons of Drosophila ntc f0259 ntc ms771 Movie S4. Three week old Fbxo7 fl/fl Cre Fbxo7 fl/fl; Cre Fbxo7 fl/fl Cre Fbxo7 fl/fl Cre Movie S5. Eight week old Fbxo7 fl/fl Cre Fbxo7 fl/fl Cre + Fbxo7 fl/fl Cre + Fbxo7 fl/fl Cre Movie S6. Another example for the ability of TgPI31 Fbxo7 Fbxo7 We thank members of the H.S. laboratory for thoughtful comments and helpful advice throughout. We would like to thank the transgenic and reproductive technology center of the Rockefeller University for their help in generating transgenic mouse strains used in this study. This work was supported by a Kestenbaum Award to Adi Minis, NIH Grant RO1GM60124, a gift from the Loewenberg Foundation, and a grant from the Cure Alzheimer’s Foundation to H.S., and generous support from the Pershing Square Foundation. Author contributions J.A.R., A.M., and H.S. designed research; J.A.R., A.M., R.A., H.H.M.N., and F.S. performed research; J.A.R. and A.M. contributed new reagents/analytic tools; J.A.R., A.M., R.A., H.H.M.N., F.S., and H.S. analyzed data; and J.A.R., A.M., and H.S. wrote the paper. Competing interests The authors declare no competing interest. This article is a PNAS Direct Submission. Data, Materials, and Software Availability All study data are included in the article and/or supporting information 1 L. C. Walker H. LeVine The cerebral proteopathies: Neurodegenerative disorders of protein conformation and assembly Mol. Neurobiol. 21 83 95 2000 11327151 10.1385/MN:21:1-2:083 2 J. Hardy A hundred years of Alzheimer’s disease research Neuron 52 3 13 2006 17015223 10.1016/j.neuron.2006.09.016 3 R. G. Canter J. Penney L. H. Tsai The road to restoring neural circuits for the treatment of Alzheimer’s disease Nature 539 187 196 2016 27830780 10.1038/nature20412 4 M. H. Glickman A. Ciechanover The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction Physiol. Rev. 82 373 428 2002 11917093 10.1152/physrev.00027.2001 5 J. P. Taylor J. Hardy K. H. Fischbeck Toxic proteins in neurodegenerative disease Science 296 1991 1995 2002 12065827 10.1126/science.1067122 6 A. Ciechanover Y. T. Kwon Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies Exp. Mol. Med. 47 e147 e147 2015 25766616 10.1038/emm.2014.117 PMC4351408 7 D. Cozachenco F. C. Ribeiro S. T. Ferreira Defective proteostasis in Alzheimer’s disease Ageing Res. Rev. 85 101862 2023 36693451 10.1016/j.arr.2023.101862 8 J. H. Weishaupt T. Hyman I. Dikic Common molecular pathways in amyotrophic lateral sclerosis and frontotemporal dementia Trends Mol. Med. 22 769 783 2016 27498188 10.1016/j.molmed.2016.07.005 9 E. M. Hol D. F. Fischer H. Ovaa W. Scheper Ubiquitin proteasome system as a pharmacological target in neurodegeneration Expert Rev. Neurother. 6 1337 1347 2006 17009921 10.1586/14737175.6.9.1337 10 R. I. Morimoto Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging Genes Dev. 22 1427 1438 2008 18519635 10.1101/gad.1657108 PMC2732416 11 Y. Ihara M. Morishima-Kawashima R. Nixon The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease Cold Spring Harb. Perspect. Med. 2 a006361 2012 22908190 10.1101/cshperspect.a006361 PMC3405832 12 P. P. Liu Y. Xie X. Y. Meng J. S. Kang History and progress of hypotheses and clinical trials for Alzheimer’s disease Signal Transduct. Target. Ther. 4 29 2019 31637009 10.1038/s41392-019-0063-8 PMC6799833 13 R. van der Kant L. S. B. Goldstein R. Ossenkoppele Amyloid-beta-independent regulators of tau pathology in Alzheimer disease Nat. Rev. Neurosci. 21 21 35 2020 31780819 10.1038/s41583-019-0240-3 14 E. E. Congdon C. Ji A. M. Tetlow Y. Jiang E. M. Sigurdsson Tau-targeting therapies for Alzheimer disease: Current status and future directions Nat. Rev. Neurol. 19 715 736 2023 37875627 10.1038/s41582-023-00883-2 PMC10965012 15 D. J. Selkoe Alzheimer’s disease is a synaptic failure Science 298 789 791 2002 12399581 10.1126/science.1074069 16 W. Yu B. Lu Synapses and dendritic spines as pathogenic targets in Alzheimer’s disease Neural Plast. 247150 2012 22474602 10.1155/2012/247150 PMC3306944 17 E. Nachman P. Verstreken Synaptic proteostasis in Parkinson’s disease Curr. Opin. Neurobiol. 72 72 79 2022 34653835 10.1016/j.conb.2021.09.001 18 D. Vilchez I. Saez A. Dillin The role of protein clearance mechanisms in organismal ageing and age-related diseases Nat. Commun. 5 5659 2014 25482515 10.1038/ncomms6659 19 S. L. Giandomenico B. Alvarez-Castelao E. M. Schuman Proteostatic regulation in neuronal compartments Trends Neurosci. 45 41 52 2022 34489114 10.1016/j.tins.2021.08.002 20 D. C. Rubinsztein The roles of intracellular protein-degradation pathways in neurodegeneration Nature 443 780 786 2006 17051204 10.1038/nature05291 21 C. Pohl I. Dikic Cellular quality control by the ubiquitin-proteasome system and autophagy Science 366 818 822 2019 31727826 10.1126/science.aax3769 22 H. C. Tai H. Besche A. L. Goldberg E. M. Schuman Characterization of the brain 26S proteasome and its interacting proteins Front. Mol. Neurosci. 3 12 2010 20717473 10.3389/fnmol.2010.00012 PMC2901091 23 I. Livneh V. Cohen-Kaplan C. Cohen-Rosenzweig N. Avni A. Ciechanover The life cycle of the 26S proteasome: From birth, through regulation and function, and onto its death Cell Res. 26 869 885 2016 27444871 10.1038/cr.2016.86 PMC4973335 24 B. Bingol M. Sheng Deconstruction for reconstruction: The role of proteolysis in neural plasticity and disease Neuron 69 22 32 2011 21220096 10.1016/j.neuron.2010.11.006 25 H. C. Tai E. M. Schuman Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction Nat. Rev. Neurosci. 9 826 838 2008 18931696 10.1038/nrn2499 26 A. N. Hegde S. C. Upadhya The ubiquitin-proteasome pathway in health and disease of the nervous system Trends Neurosci. 30 587 595 2007 17950927 10.1016/j.tins.2007.08.005 27 I. J. Cajigas T. Will E. M. Schuman Protein homeostasis and synaptic plasticity EMBO J. 29 2746 2752 2010 20717144 10.1038/emboj.2010.173 PMC2924649 28 J. J. Yi M. D. Ehlers Ubiquitin and protein turnover in synapse function Neuron 47 629 632 2005 16129392 10.1016/j.neuron.2005.07.008 29 M. Kuijpers Keeping synapses in shape: Degradation pathways in the healthy and aging brain Signal 6 NS20210063 2022 10.1042/NS20210063 PMC9208270 35813265 30 F. Turker E. K. Cook S. S. Margolis The proteasome and its role in the nervous system Cell Chem. Biol. 28 903 917 2021 33905676 10.1016/j.chembiol.2021.04.003 PMC8286317 31 B. Bingol E. M. Schuman Activity-dependent dynamics and sequestration of proteasomes in dendritic spines Nature 441 1144 1148 2006 16810255 10.1038/nature04769 32 K. Liu PI31 is an adaptor protein for proteasome transport in axons and required for synaptic development Dev. Cell 50 509 524 2019 31327739 10.1016/j.devcel.2019.06.009 PMC6702053 33 M. Bader A conserved F box regulatory complex controls proteasome activity in Drosophila Cell 145 371 382 2011 21529711 10.1016/j.cell.2011.03.021 PMC3108249 34 H. Yashiroda N-terminal alpha7 deletion of the proteasome 20S core particle substitutes for yeast PI31 function Mol. Cell. Biol. 35 141 152 2015 25332237 10.1128/MCB.00582-14 PMC4295373 35 A. Minis The proteasome regulator PI31 is required for protein homeostasis, synapse maintenance, and neuronal survival in mice Proc. Natl. Acad. Sci. U.S.A. 116 24639 24650 2019 31754024 10.1073/pnas.1911921116 PMC6900516 36 B. J. Yang Arabidopsis PROTEASOME REGULATOR1 is required for auxin-mediated suppression of proteasome activity and regulates auxin signalling Nat. Commun. 7 11388 2016 27109828 10.1038/ncomms11388 PMC4848511 37 M. Chu-Ping C. A. Slaughter G. N. DeMartino Purification and characterization of a protein inhibitor of the 20S proteasome (macropain) Biochim. Biophys. Acta 1119 303 311 1992 1312359 10.1016/0167-4838(92)90218-3 38 P. F. Cho-Park H. Steller Proteasome regulation by ADP-ribosylation Cell 153 614 627 2013 23622245 10.1016/j.cell.2013.03.040 PMC3676968 39 S. Shojaee Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays Am. J. Hum. Genet. 82 1375 1384 2008 18513678 10.1016/j.ajhg.2008.05.005 PMC2427312 40 A. Di Fonzo FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome Neurology 72 240 245 2009 19038853 10.1212/01.wnl.0000338144.10967.2b 41 C. Paisan-Ruiz Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations Mov. Disord. 25 1791 1800 2010 20669327 10.1002/mds.23221 PMC6005705 42 L. Zhao A rare variant nonparametric linkage method for nuclear and extended pedigrees with application to late-onset Alzheimer disease via WGS data Am. J. Hum. Genet. 105 822 835 2019 31585107 10.1016/j.ajhg.2019.09.006 PMC6817540 43 S. R. W. Stott Loss of FBXO7 results in a Parkinson’s-like dopaminergic degeneration via an RPL23-MDM2-TP53 pathway J. Pathol. 249 241 254 2019 10.1002/path.5312 31144295 PMC6790581 44 F. Magrinelli PSMF1 variants cause a phenotypic spectrum from early-onset Parkinson’s disease to perinatal lethality by disrupting mitochondrial pathways 2024 10.1101/2024.06.19.24308302 45 Y. Zhong J. Li M. Ye X. Jin The characteristics of FBXO7 and its role in human diseases Gene 851 146972 2023 36261086 10.1016/j.gene.2022.146972 46 S. Joseph J. B. Schulz J. Stegmuller Mechanistic contributions of FBXO7 to Parkinson disease J. Neurochem. 144 118 127 2018 29134665 10.1111/jnc.14253 47 S. J. Randle H. Laman Structure and function of Fbxo7/PARK15 in Parkinson’s disease Curr. Protein Pept. Sci. 18 715 724 2017 26965690 10.2174/1389203717666160311121433 48 S. Vingill Loss of FBXO7 (PARK15) results in reduced proteasome activity and models a parkinsonism-like phenotype in mice EMBO J. 35 2008 2025 2016 27497298 10.15252/embj.201593585 PMC5282834 49 S. Al Rawi Study of an FBXO7 patient mutation reveals Fbxo7 and PI31 co-regulate proteasomes and mitochondria FEBS J. 291 2565 2589 2024 38466799 10.1111/febs.17114 50 A. Sanchez-Martinez A. Martinez A. J. Whitworth FBXO7/ntc and USP30 antagonistically set the ubiquitination threshold for basal mitophagy and provide a target for Pink1 phosphorylation in vivo PLoS Biol. 21 e3002244 2023 37535686 10.1371/journal.pbio.3002244 PMC10427020 51 T. Kreko-Pierce B. A. Eaton The Drosophila J. Cell Sci. 130 3388 3398 2017 28808087 10.1242/jcs.207027 PMC5665441 52 C. C. Rathje A conserved requirement for Fbxo7 during male germ cell cytoplasmic remodeling Front. Physiol. 10 1278 2019 31649556 10.3389/fphys.2019.01278 PMC6795710 53 C. Ballesteros Reviriego FBXO7 sensitivity of phenotypic traits elucidated by a hypomorphic allele PLoS ONE 14 e0212481 2019 30840666 10.1371/journal.pone.0212481 PMC6402633 54 M. S. Brill Branch-specific microtubule destabilization mediates axon branch loss during neuromuscular synapse elimination Neuron 92 845 856 2016 27773584 10.1016/j.neuron.2016.09.049 PMC5133389 55 X. Zhan Generation of BAF53b-Cre transgenic mice with pan-neuronal Cre activities Genesis 53 440 448 2015 26077106 10.1002/dvg.22866 PMC4514543 56 J. Wang Loss of the parkinsonism-associated protein FBXO7 in glutamatergic forebrain neurons in mice leads to abnormal motor behavior and synaptic defects J. Neurochem. 167 296 317 2023 37753846 10.1111/jnc.15962 57 S. Joseph Myelinating glia-specific deletion of Fbxo7 in mice triggers axonal degeneration in the central nervous system together with peripheral neuropathy J. Neurosci. 39 5606 5626 2019 31085610 10.1523/JNEUROSCI.3094-18.2019 PMC6616290 58 C. Parra Bravo S. A. Naguib L. Gan Cellular and pathological functions of tau Nat. Rev. Mol. Cell Biol. 25 845 864 2024 39014245 10.1038/s41580-024-00753-9 59 M. Arrasate M. Perez J. Avila Tau dephosphorylation at tau-1 site correlates with its association to cell membrane Neurochem. Res. 25 43 50 2000 10685603 10.1023/a:1007583214722 60 M. J. Ellis Identification of high-performing antibodies for the reliable detection of tau proteoforms by western blotting and immunohistochemistry Acta Neuropathol. 147 87 2024 38761203 10.1007/s00401-024-02729-7 PMC11102361 61 J. W. Harper B. A. Schulman Cullin-ring ubiquitin ligase regulatory circuits: A quarter century beyond the F-box hypothesis Annu. Rev. Biochem. 90 403 429 2021 33823649 10.1146/annurev-biochem-090120-013613 PMC8217159 62 V. S. Burchell The Parkinson’s disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy Nat. Neurosci. 16 1257 1265 2013 23933751 10.1038/nn.3489 PMC3827746 63 T. Huang Fbxo7 and Pink1 play a reciprocal role in regulating their protein levels Aging (Albany NY) 13 77 88 2020 33291077 10.18632/aging.202236 PMC7835017 64 Y. Liu Chemical inhibition of FBXO7 reduces inflammation and confers neuroprotection by stabilizing the mitochondrial kinase PINK1 JCI Insight 5 e131834 2020 32493843 10.1172/jci.insight.131834 PMC7308049 65 F. Kraus PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems EMBO Rep. 24 e56399 2023 37334901 10.15252/embr.202256399 PMC10398645 66 Z. D. Zhou F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy Hum. Mol. Genet. 24 6314 6330 2015 26310625 10.1093/hmg/ddv340 67 M. Delgado-Camprubi N. Esteras M. P. Soutar H. Plun-Favreau A. Y. Abramov Deficiency of Parkinson’s disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation Cell Death Differ. 24 120 131 2017 27689878 10.1038/cdd.2016.104 PMC5260490 68 S. Noda Impaired mitochondrial accumulation and Lewy pathology in neuron-specific FBXO7-deficient mice Mol. Brain 15 54 2022 35701754 10.1186/s13041-022-00936-5 PMC9199167 69 Z. D. Zhou J. C. T. Lee E. K. Tan Pathophysiological mechanisms linking F-box only protein 7 (FBXO7) and Parkinson’s disease (PD) Mutat. Res. Rev. 778 72 78 2018 10.1016/j.mrrev.2018.10.001 30454685 70 G. A. Collins A. L. Goldberg The logic of the 26S proteasome Cell 169 792 806 2017 28525752 10.1016/j.cell.2017.04.023 PMC5609836 71 S. Keck R. Nitsch T. Grune O. Ullrich Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease J. Neurochem. 85 115 122 2003 12641733 10.1046/j.1471-4159.2003.01642.x 72 H. C. Tai The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system Am. J. Pathol. 181 1426 1435 2012 22867711 10.1016/j.ajpath.2012.06.033 PMC3463637 73 T. A. Thibaudeau R. T. Anderson D. M. Smith A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers Nat. Commun. 9 1097 2018 29545515 10.1038/s41467-018-03509-0 PMC5854577 74 N. F. Bence R. M. Sampat R. R. Kopito Impairment of the ubiquitin-proteasome system by protein aggregation Science 292 1552 1555 2001 11375494 10.1126/science.292.5521.1552 75 A. Karpova Neuronal autophagy in the control of synapse function Neuron 113 974 990 2025 10.1016/j.neuron.2025.01.019 40010347 76 S. E. Hill D. A. Colon-Ramos The journey of the synaptic autophagosome: A cell biological perspective Neuron 105 961 973 2020 32191859 10.1016/j.neuron.2020.01.018 77 C. Sun An abundance of free regulatory (19S) proteasome particles regulates neuronal synapses Science 380 eadf2018 2023 37228199 10.1126/science.adf2018 78 F. Turker A. Brennan S. S. Margolis Neuronal membrane proteasome-derived peptides modulate NMDAR-dependent neuronal signaling to promote changes in gene expression Mol. Biol. Cell 35 ar6 2024 37910253 10.1091/mbc.E23-06-0218 PMC10881162 79 E. Villalon Landeros The nociceptive activity of peripheral sensory neurons is modulated by the neuronal membrane proteasome Cell Rep. 43 114058 2024 38614084 10.1016/j.celrep.2024.114058 PMC11157458 80 H. Y. He Neuronal membrane proteasomes regulate neuronal circuit activity in vivo and are required for learning-induced behavioral plasticity Proc. Natl. Acad. Sci. U.S.A. 120 e2216537120 2023 36630455 10.1073/pnas.2216537120 PMC9934054 81 K. V. Ramachandran Activity-dependent degradation of the nascentome by the neuronal membrane proteasome Mol. Cell 71 169 177.e166 2018 29979964 10.1016/j.molcel.2018.06.013 PMC6070390 82 C. Tapia-Rojas It’s all about tau Prog. Neurobiol. 175 54 76 2019 30605723 10.1016/j.pneurobio.2018.12.005 PMC6397676 83 A. B. Meriin V. L. Gabai J. Yaglom V. I. Shifrin M. Y. Sherman Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis J. Biol. Chem. 273 6373 6379 1998 9497367 10.1074/jbc.273.11.6373 84 G. N. Patrick P. Zhou Y. T. Kwon P. M. Howley L. H. Tsai P35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway J. Biol. Chem. 273 24057 24064 1998 9727024 10.1074/jbc.273.37.24057 85 T. Kimura K. Ishiguro S. Hisanaga Physiological and pathological phosphorylation of tau by Cdk5 Front. Mol. Neurosci. 7 65 2014 25076872 10.3389/fnmol.2014.00065 PMC4097945 86 Y. Chu Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease Brain 147 444 457 2024 38006313 10.1093/brain/awad388 PMC10834249 87 E. S. Chocron Genetic and pharmacologic proteasome augmentation ameliorates Alzheimer’s-like pathology in mouse and fly APP overexpression models Sci. Adv. 8 eabk2252 2022 35675410 10.1126/sciadv.abk2252 PMC9177073 88 B. Boland Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing Nat. Rev. Drug Discov. 17 660 688 2018 30116051 10.1038/nrd.2018.109 PMC6456907 89 L. Xu Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: From bench to bedside J. Transl. Med. 22 866 2024 39334366 10.1186/s12967-024-05661-2 PMC11429861 90 Q. Ling J. A. Herstine A. Bradbury S. J. Gray AAV-based in vivo gene therapy for neurological disorders Nat. Rev. Drug Discov. 22 789 806 2023 37658167 10.1038/s41573-023-00766-7 91 J. H. Wang D. J. Gessler W. Zhan T. L. Gallagher G. Gao Adeno-associated virus as a delivery vector for gene therapy of human diseases Signal Transduct. Target. Ther. 9 78 2024 38565561 10.1038/s41392-024-01780-w PMC10987683 92 S. Wang L. Xiao Progress in AAV-mediated in vivo gene therapy and its applications in central nervous system diseases Int. J. Mol. Sci. 26 2213 2025 40076831 10.3390/ijms26052213 PMC11899905 Supporting Information ",
  "metadata": {
    "Title of this paper": "Progress in AAV-mediated in vivo gene therapy and its applications in central nervous system diseases",
    "Journal it was published in:": "Proceedings of the National Academy of Sciences of the United States of America",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12478140/"
  }
}